JPRN-UMIN000037603已完成未知
ong-term efficacy and safety of the GLP-1 receptor agonist liraglutide in Japanese patients with type 2 diabetes mellitus. - Long-term efficacy and safety of the GLP-1 receptor agonist liraglutide in Japanese patients with type 2 diabetes mellitus.
akakinen clinic0 个研究点目标入组 1,000 人开始时间: 2019年8月6日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 1,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Participation in the study is judged by the investigator or sub-investigator as inappropriate for any other reason
研究者
相似试验
招募中
不适用
Comparing effects of a long acting GLP-1 receptor agonist liraglutide with a short acting GLP-1 receptor agonist lixisenatide on diabetic cardiac autonomic neuropathy and glycemic variability evaluated by power spectral analysis of 24-hr heart rate and continuous glucose monitoring.Type 2 diabetesJPRN-UMIN000017144Department of Endocrinology and Metabolism, Dokkyo Medical University30
进行中（未招募）
不适用
Effects of once-daily administered GLP-1 Receptoragonist Lixisenatide in combination with basal Insulin on glycemic control in patients with type-2 diabetes mellitus not achieving therapeutic targets with premixed insulin strategy10 patients (both gender) under treatment with premixed insulin (2-3 injections) and HbA1c>7% will be switched to basal insulin glargine (Lantus, once daily) and GLP-1 receptor agonist Lixisenatide (Lyxumia, once daily).EUCTR2013-005334-37-ATMedical University of Vienna / Medizinische Universität Wien
招募中
不适用
Observation of using GLP-1 receptor agonist for wellness of brain activity in type 2 diabetes patients with mild cognitive impairmentJPRN-UMIN000030840Ogawa Red Cross Hospital50
已完成
不适用
Study of the clinical effect of GLP-1 analogue for body weight, body fat, insulin secretion in patients with type 2 diabetesJPRN-UMIN000009638Division of Nephrology, Endocrinology and Metabolism, Department of Internal Medicine, Tokai University School of Medicine130
已完成
不适用
Efficacy and Safety of GLP-1 first therapy compared with Insulin GLP-1 relay therapy in type 2 diabetes with inadequate glucose control: a randomized, open-label, multicenter parallel-group studyType 2 diabetesJPRN-UMIN000014140Kanazawa university Department of Disease Control and Homeostasis120